share_log

Grabar Law Office Investigates Potential Claims Against Officers and Directors of Odonate Therapeutics, Inc. After an Agreement Is Reached to Settle Class Action

Grabar Law Office Investigates Potential Claims Against Officers and Directors of Odonate Therapeutics, Inc. After an Agreement Is Reached to Settle Class Action

Grabar律師事務所在達成集體訴訟和解協議後調查針對Odonate治療公司高管和董事的潛在索賠
newsfile ·  2022/05/10 22:40

Philadelphia, Pennsylvania--(Newsfile Corp. - May 10, 2022) - Odonate Therapeutics Inc. (NASDAQ: ODT) (OTC Pink: ODTC) has agreed to pay $12.5 million to resolve a proposed securities class action in alleging the pharmaceutical company misled investors about the safety of a new drug for treating cancer. The lawsuit accused the company of making misleading statements and omissions about the development of tesetaxel. The amended complaint alleged that the company and its officers unlawfully inflated the stock price by misleading investors about a clinical trial and the likelihood of FDA approval.

賓夕法尼亞州費城-(Newsfile Corp.-2022年5月10日)-Odonate Treateutics Inc.(場外交易代碼:ODTC)已同意支付1,250萬美元了結擬議中的證券集體訴訟,指控該製藥公司在一種治療癌症的新藥的安全性上誤導投資者。訴訟指控該公司在泰他賽的開發方面做出了誤導性的陳述和遺漏。修改後的起訴書稱,該公司及其官員通過在臨牀試驗和FDA批准的可能性上誤導投資者,非法抬高了股價。

Current Odonate shareholders who have held shares of Odonate stock since at least December 7, 2017, can seek corporate reforms, the return of funds back to company coffers, and potentially a court approved incentive award if appropriate.

至少從2017年12月7日開始持有Odonate股票的現任Odonate股東可以尋求公司改革,將資金返還公司金庫,如果合適,還可能獲得法院批准的激勵獎勵。

If you would like to learn more about this matter at no cost to you, please contact us at jgrabar@grabarlaw.com or call 267-507-6085.

如果您想免費了解更多有關此事的信息,請通過jgrabar@grabarlaw.com或致電267-507-6085與我們聯繫。

Attorney Advertising Disclaimer

律師廣告免責聲明

These materials have been prepared by the Grabar Law Office for informational purposes only and does not constitute legal advice. This information is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Prior results referred to in these materials do not guarantee or suggest a similar result in other matters.

這些材料由Grabar律師事務所編寫,僅供參考,不構成法律諮詢。這些信息並不是為了建立律師與委託人之間的關係,也不構成律師與當事人之間的關係。這些材料中提到的以前的結果並不保證或暗示在其他事項上也會有類似的結果。

Contact:

聯繫方式:

Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com

作者:Joshua H.Grabar,Esq.
格拉巴律師事務所
一個自由之地
市場街1650號,套房3600
賓夕法尼亞州費城,郵編19103
電話:267-507-6085
電子郵件:jgrabar@grabarlaw.com

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論